Double attack on tough lymphoma: stem cell transplant plus CAR-T shows promise
NCT ID NCT06365671
First seen Jan 07, 2026 · Last updated Jun 11, 2026 · Updated 22 times
Summary
This study tests whether giving a special immune cell treatment (CD19 CAR-T) right after a stem cell transplant can help people with a hard-to-treat type of B-cell lymphoma. The trial involves 16 adults whose cancer has come back or not responded to standard treatments. The main goal is to see how many patients achieve complete remission within three months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.